T-DM1 meets OS endpoint

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit said T-DM1 met the co-primary endpoint of improving overall survival vs. Tykerb lapatinib plus

Read the full 226 word article

User Sign In